[go: up one dir, main page]

PE20161245A1 - Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos - Google Patents

Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos

Info

Publication number
PE20161245A1
PE20161245A1 PE2016001574A PE2016001574A PE20161245A1 PE 20161245 A1 PE20161245 A1 PE 20161245A1 PE 2016001574 A PE2016001574 A PE 2016001574A PE 2016001574 A PE2016001574 A PE 2016001574A PE 20161245 A1 PE20161245 A1 PE 20161245A1
Authority
PE
Peru
Prior art keywords
insulin
receptor
growth factor
seq
specific antibodies
Prior art date
Application number
PE2016001574A
Other languages
English (en)
Inventor
Mehdi Arbabi-Ghahroudi
Renald Gilbert
Arsalan S Haqqani
Traian Sulea
Bernard Massie
Danica Stanimirovic
Kristin KEMMERICH
Original Assignee
Nat Res Council Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Res Council Canada filed Critical Nat Res Council Canada
Publication of PE20161245A1 publication Critical patent/PE20161245A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • G01N33/5759—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a un anticuerpo unido a un epitopo del receptor del factor 1 de crecimiento similar a la insulina (IGF1R), que comprende una region CDR1 de SEQ ID NO:1; una region CDR 2 de SEQ ID NO:2 y una region CDR3 de SEQ ID NO:3. Tambien se refiere a una composicion, un metodo de deteccion de IGF1R y un metodo de administracion. Dichos anticuerpos y fragmentos de los mismos transmigran la barrera hematoencefalica siendo utiles en el tratamiento de enfermedades que se originan en el cerebro
PE2016001574A 2014-03-06 2014-12-04 Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos PE20161245A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461948831P 2014-03-06 2014-03-06

Publications (1)

Publication Number Publication Date
PE20161245A1 true PE20161245A1 (es) 2016-11-25

Family

ID=54054288

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001574A PE20161245A1 (es) 2014-03-06 2014-12-04 Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos

Country Status (18)

Country Link
US (1) US10100117B2 (es)
EP (1) EP3114140B1 (es)
JP (1) JP6541236B2 (es)
KR (1) KR102355309B1 (es)
CN (1) CN106536555B (es)
AU (1) AU2014385801B2 (es)
BR (1) BR112016020643B1 (es)
CA (1) CA2941654C (es)
CL (1) CL2016002245A1 (es)
DK (1) DK3114140T3 (es)
EA (1) EA035517B1 (es)
IL (1) IL247607B (es)
MX (1) MX375841B (es)
NZ (1) NZ724869A (es)
PE (1) PE20161245A1 (es)
UA (1) UA120047C2 (es)
WO (1) WO2015131258A1 (es)
ZA (1) ZA201606212B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX375841B (es) 2014-03-06 2025-03-07 Nat Res Council Canada Anticuerpos especificos para el receptor del factor de crecimiento similar a insulina 1 y usos de los mismos.
US10112998B2 (en) 2014-03-06 2018-10-30 National Research Council Of Canada Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
AU2014385799B2 (en) 2014-03-06 2020-10-22 National Research Council Of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
AU2017293450B2 (en) * 2016-07-06 2024-08-08 National Research Council Of Canada Humanized antibodies transmigrating the blood-brain barrier and uses thereof
BR112019013953A2 (pt) 2017-01-06 2020-02-11 Abl Bio Inc. Anticorpo anti-a-syn e uso do mesmo
CA3052058A1 (en) 2017-01-30 2018-08-02 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
JP7204235B2 (ja) 2017-08-02 2023-01-16 ストレスマーク・バイオサイエンシーズ・インコーポレイテッド 活性型α－シヌクレインに結合する抗体
KR102263812B1 (ko) * 2017-12-14 2021-06-14 에이비엘바이오 주식회사 a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도
US12344671B2 (en) 2018-04-24 2025-07-01 National Research Council Of Canada Blood-brain barrier transmigrating therapeutic compounds and uses thereof
BR112021013559A2 (pt) * 2019-01-09 2021-09-21 Vect-Horus Moléculas de ligação a receptor de transferrina, conjugados das mesmas e seus usos
BR112021025086A2 (pt) * 2019-06-14 2022-01-25 Abl Bio Inc Anticorpo biespecífico contra a-syn/igfir e uso do mesmo
TWI766512B (zh) 2020-01-02 2022-06-01 瑞士商赫孚孟拉羅股份公司 用於判定腦中的治療性抗體量之方法
WO2024132147A1 (en) * 2022-12-22 2024-06-27 Lifearc Galanin-2 receptor agonists

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0711303B2 (en) 1993-07-30 2009-06-10 Affymax, Inc. Biotinylation of proteins
AU6607100A (en) 1999-07-23 2001-02-13 Regents Of The University Of California, The Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
CA2380443C (en) * 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
ES2306794T3 (es) 2001-11-30 2008-11-16 National Research Council Of Canada Moleculas de autoensamblaje.
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050142141A1 (en) * 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
EP1452601A1 (en) 2003-02-28 2004-09-01 Roche Diagnostics GmbH Enhanced expression of fusion polypeptides with a biotinylation tag
WO2007000328A1 (en) * 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
JP5269597B2 (ja) 2005-09-27 2013-08-21 ナショナル リサーチ カウンシル オブ カナダ 血液―脳隔壁エピトープとその利用
CN101321784A (zh) * 2005-10-11 2008-12-10 埃博灵克斯股份有限公司 针对egfr和igf－ir的纳米抗体tm和多肽
US20090252681A1 (en) * 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR
US7981417B2 (en) 2006-06-07 2011-07-19 Wisconsin Alumni Research Foundation Blood-brain barrier targeting anti-bodies
EP2029621A2 (en) 2006-06-07 2009-03-04 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
JP5959795B2 (ja) 2006-08-18 2016-08-02 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 血液脳関門送達のための物質
EP2197490A2 (en) 2007-08-28 2010-06-23 Biogen Idec MA, Inc. Compositions that bind multiple epitopes of igf-1r
US8444976B2 (en) * 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
PL2485761T3 (pl) * 2009-10-09 2019-10-31 Armagen Inc Sposoby i kompozycje do zwiększania aktywności 2-sulfatazy iduronianu w cns
US8444982B2 (en) * 2009-12-04 2013-05-21 The University Of Hong Kong Anti-IGF-IR antibodies and uses thereof
EP2558503B1 (en) 2010-04-14 2015-12-09 National Research Council of Canada Compositions and methods for brain delivery of analgesic peptides
UA107596C2 (uk) * 2010-05-27 2015-01-26 Виділений поліпептид, який зв'язується з рецептором інсуліноподібного фактора росту 1
US20120171120A1 (en) 2010-11-30 2012-07-05 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
DK2802606T3 (en) * 2012-01-10 2018-06-25 Biogen Ma Inc INCREASE TRANSPORT OF THERAPEUTIC MOLECULES OVER THE BLOOD-BRAIN BARRIER
AU2014385799B2 (en) 2014-03-06 2020-10-22 National Research Council Of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
MX375841B (es) 2014-03-06 2025-03-07 Nat Res Council Canada Anticuerpos especificos para el receptor del factor de crecimiento similar a insulina 1 y usos de los mismos.
US10112998B2 (en) 2014-03-06 2018-10-30 National Research Council Of Canada Insulin-like growth factor 1 receptor-specific antibodies and uses thereof

Also Published As

Publication number Publication date
MX2016011557A (es) 2017-04-13
BR112016020643B1 (pt) 2023-05-02
JP6541236B2 (ja) 2019-07-10
ZA201606212B (en) 2019-01-30
BR112016020643A2 (en) 2018-01-23
CA2941654A1 (en) 2015-09-11
EP3114140A4 (en) 2017-10-25
CL2016002245A1 (es) 2017-04-07
CN106536555A (zh) 2017-03-22
CN106536555B (zh) 2019-10-18
EP3114140A1 (en) 2017-01-11
US10100117B2 (en) 2018-10-16
AU2014385801B2 (en) 2020-11-12
KR102355309B1 (ko) 2022-01-24
NZ724869A (en) 2022-07-01
IL247607B (en) 2020-03-31
EA201691782A1 (ru) 2017-01-30
US20170015748A1 (en) 2017-01-19
WO2015131258A1 (en) 2015-09-11
JP2017513461A (ja) 2017-06-01
UA120047C2 (uk) 2019-09-25
MX375841B (es) 2025-03-07
AU2014385801A1 (en) 2016-10-20
KR20160130436A (ko) 2016-11-11
CA2941654C (en) 2023-08-08
DK3114140T3 (da) 2019-06-03
EA035517B1 (ru) 2020-06-29
IL247607A0 (en) 2016-11-30
EP3114140B1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
PE20161245A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
PE20161311A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
AR096687A1 (es) Anticuerpos anti-fcrh5
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
PE20150025A1 (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
CO2017001919A2 (es) Anticuerpos anti-her2 e inmunoconjugados
PE20170953A1 (es) ANTICUERPOS ANTI-CD79b Y METODOS DE USO
PE20191079A1 (es) Inmunoglobulinas y usos de estas
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
AR101829A1 (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
PE20180499A1 (es) Anticuerpos de union a tau
AR091701A1 (es) Anticuerpos anti-cd22 e inmunoconjugados
PE20190737A1 (es) Anticuerpos anti-cd27
CL2016002547A1 (es) Anticuerpos contra her2 biespecíficos
AR107290A1 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
PE20141562A1 (es) Anticuerpos anti-htra1 y metodos de uso
NZ727024A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
WO2015157252A8 (en) Treatment of cancer using anti-cd19 chimeric antigen receptor
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
PE20161221A1 (es) Anticuerpos de il-21
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos